JPMorgan Chase & Co. Reduces Stake in REGENXBIO Inc. to 4.4%

JPMorgan Chase & Co. filed a Schedule 13G/A on June 4, 2026, disclosing a reduction in its ownership position in REGENXBIO Inc. (RGNX). As of the event date on May 29, 2026, the financial institution reported beneficial ownership of 2,279,362 shares of common stock, representing 4.4% of the company. This filing marks Amendment No. 7, indicating a decrease from previous levels and bringing the firm's stake below the 5% reporting threshold. Of the total shares held, JPMorgan maintains sole voting power over 2,104,445 shares and sole dispositive power over all 2,279,362 shares. The securities are held across various subsidiaries, including J.P. Morgan Securities LLC, JPMorgan Chase Bank, N.A., and J.P. Morgan Investment Management Inc. The filing includes a certification that the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. REGENXBIO Inc. is a clinical-stage biotechnology company headquartered in Rockville, Maryland.